Figure 2: Gross benefit according to global efficacy of the screening method for the 5 years of follow-up. Global efficacy ρ = α.β.γ with α = penetration of the screening method in diabetic population, β = stabilization rate i.e. percentage of patients that should have migrated from a stage to the following one and that do not move due to screening of complication with total compliance of patients to recommendations as it could be observed in a perfect clinical trial and γ = compliance of patients to recommendations issued from the diagnosis of small fiber neuropathy in usual practice. In our examples 6% was chosen as global efficacy.